Toxicology

ZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on Benzinga All Access

Retrieved on: 
Wednesday, January 10, 2024
Entrepreneurship, Patient, Therapy, Proteinuria, Diabetic nephropathy, Toxicology, GLP, Interview, Structural Damage, Initial public offering, Kidney disease, Environment, Optimism, IND, Inflammasome, Inflammation, VAR, Investigational New Drug, DKD, Pharmaceutical industry

During the interview, Mr. Glover described the significant unmet need and market opportunity in kidney disease, and how ZyVersa’s Cholesterol Efflux MediatorTM VAR 200 has the potential to improve kidney function and reduce kidney disease progression.

Key Points: 
  • During the interview, Mr. Glover described the significant unmet need and market opportunity in kidney disease, and how ZyVersa’s Cholesterol Efflux MediatorTM VAR 200 has the potential to improve kidney function and reduce kidney disease progression.
  • Current treatments target glomerular hypertension and inflammation, but there are no treatments that target lipid accumulation, which is known to contribute to structural damage, proteinuria, and progression of kidney disease.
  • ZyVersa plans to initiate a Phase 2a trial with VAR 200 in patients with diabetic kidney disease (DKD) in the first quarter of 2024, with preliminary data anticipated by mid-year 2024.
  • ZyVersa plans to complete GLP toxicology studies with IC 100 and submit an Investigational New Drug (IND) application in the fourth quarter of 2024, followed by initiation of a Phase 1 trial.

Vect-Horus Strengthens its Scientific Advisory Board with the Appointment of Pr. Xavier Declèves

Retrieved on: 
Thursday, January 11, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Faculty, Toxicology, Pharmacy, BBB, Head, SAB, Pharmacokinetics, Blood–brain barrier, CNS

Xavier Declèves to its scientific advisory board (SAB).

Key Points: 
  • Xavier Declèves to its scientific advisory board (SAB).
  • Jean-Manuel Péan, Chief Scientific Officer of Vect-Horus commented, “We are pleased to welcome Xavier in our SAB.
  • Declèves, our SAB now has a tremendous level of scientific expertise that will be instrumental in advancing our technology and programs.
  • “ I'm delighted to join the Vect-Horus Advisory Board and share my expertise and ideas around targeting technologies dedicated to modern therapeutic modalities ” commented Xavier Declèves.

Chemical Insights Research Institute Commits to Public Health Research with the Opening of New Laboratories

Retrieved on: 
Thursday, January 11, 2024
Environment, Research, Natural Disasters, Chemicals, Plastics, Environmental Health, Manufacturing, Health, General Health, Science, Exposure science, University, Toxicology, Policy, CIRI, Duke, Knowledge, Georgia Tech, Public, Water, Interim, Laboratory, Toxicity, Atmosphere, Harvard University, Nursing

Chemical Insights Research Institute (CIRI) of UL Research Institutes confirmed its commitment to protecting environmental and human health when it opened its new research laboratories supporting scientific studies of environmental exposure and its societal health impact.

Key Points: 
  • Chemical Insights Research Institute (CIRI) of UL Research Institutes confirmed its commitment to protecting environmental and human health when it opened its new research laboratories supporting scientific studies of environmental exposure and its societal health impact.
  • CIRI’s staff of more than two dozen research scientists, educators, and communicators are tackling critical issues on emerging environmental health threats facing people and the planet today.
  • Partnering with renowned research institutions such as the Massachusetts Institute of Technology, Georgia Institute of Technology, Duke, Harvard, Emory, and other universities, helps to expand CIRI’s research platform for knowledge.
  • “This is a proud moment for UL Research Institutes (ULRI),” said Chris Cramer, Ph.D., Interim President and Chief Research Officer of ULRI.

LadRx Issues 2024 Update to Shareholders

Retrieved on: 
Tuesday, January 9, 2024
Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, LADR, Hand, Toxicology, Zebra, GMP, Sale, OTCQB, Good laboratory practice, IND, Food, Human, NDA, Therapy, Investigational New Drug, New Drug Application, Patent, Pharmaceutical industry

LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today issued the below letter to shareholders providing a corporate update and anticipated milestones for 2024 regarding arimoclomol and LADR-7.

Key Points: 
  • LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today issued the below letter to shareholders providing a corporate update and anticipated milestones for 2024 regarding arimoclomol and LADR-7.
  • On January 8, 2024, Zevra announced the acceptance of the arimoclomol NDA by the FDA, with a Prescription Drug User Fee Act (“PDUFA”) date of June 21, 2024, triggering a $1 million payment obligation from XOMA to LadRx.
  • The second milestone related to arimoclomol is the first commercial sale of arimoclomol by Zevra, which triggers an additional $1 million payment from XOMA to LadRx (which will net LadRx $600,000).
  • We look forward to continuing to build on our momentum at LadRx and a successful 2024.

National Korea Maritime and Ocean University Researchers Explore the Impact of Microplastics and Toxin Exposure on Goldfish

Retrieved on: 
Thursday, January 11, 2024
Endocrine system, BAP, Toxicology, Health, DNA, Biochemistry, DNA repair, Plastic, Travel, Goldfish, Toxicity, Food chain, Pharmacology, Microplastics, Aquaculture

The presence of microplastics, ranging in size from 100 nanometers to 5 millimeters, is particularly concerning.

Key Points: 
  • The presence of microplastics, ranging in size from 100 nanometers to 5 millimeters, is particularly concerning.
  • Another aspect of microplastic pollution, often overlooked but equally dangerous, is their ability to absorb and carry harmful chemicals, such as persistent organic pollutants.
  • Understanding the extent of toxicity and threat posed by the combined impact of exposure to microplastics and other pollutants is, therefore, important.
  • In a recent study now, researchers led by Dr. Cheol Young Choi from National Korea Maritime and Ocean University explored the impact of microplastic and BaP exposure on freshwater goldfish (Carassius auratus), who were exposed to BaP and microplastics individually and in combination, to understand their exposure effects.

Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities

Retrieved on: 
Friday, January 5, 2024
Hereditary angioedema, Quality of life, Conference, Toxicology, Reason (argument), IND, Scale, Research, FDA, Executive Committee, Bradykinin receptor B2, Attack, Patient satisfaction, Angioedema, Trial of the century, Incidence, American Academy, Annual general meeting, AAAAI, Doctor of Philosophy, ACE, Virtual, Safety, Publication, ODT, Therapy, HAE, General Atlantic, Pharmaceutical industry

“Pharvaris enters the new year having demonstrated deucrictibant’s potential to be the preferred option for both the prevention and treatment of HAE attacks,” said Berndt Modig, Chief Executive Officer of Pharvaris.

Key Points: 
  • “Pharvaris enters the new year having demonstrated deucrictibant’s potential to be the preferred option for both the prevention and treatment of HAE attacks,” said Berndt Modig, Chief Executive Officer of Pharvaris.
  • The next years will be incredibly important to the company, and Jochen’s continued strategic guidance will be invaluable.”
    Anticipated initiation of RAPIDe-3 within 1H2024.
  • Jochen Knolle, Ph.D., co-founder of Pharvaris, transitions to strategic advisor to the CEO and Executive Committee.
  • I look forward to continuing to contribute to the strategic transformation of Pharvaris in my new capacity.”
    Oppenheimer 34th Annual Healthcare Life Sciences Conference.

Third Harmonic Bio Appoints Christopher Murphy as Chief Financial and Business Officer and Provides Business Update

Retrieved on: 
Thursday, January 4, 2024
Marketing, Toxicology, Partnership, Amgen, IND, Teprotumumab, Inflammation, KIT, Graves' ophthalmopathy, SAN, Therapy, Horizon, Medicine, Management

SAN FRANCISCO, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Christopher Murphy as Chief Financial and Business Officer. Chris brings extensive experience in business development, commercial operations, corporate strategy and investment banking in the biopharmaceutical industry to the company’s leadership team. In his role, Chris will be responsible for strategic leadership and direction of the company’s finance, corporate strategy, and business development functions.

Key Points: 
  • Chris brings extensive experience in business development, commercial operations, corporate strategy and investment banking in the biopharmaceutical industry to the company’s leadership team.
  • In his role, Chris will be responsible for strategic leadership and direction of the company’s finance, corporate strategy, and business development functions.
  • In business development, Chris was most recently Group Vice President, where he oversaw a number of strategic transactions and integrations.
  • The company maintains a strong financial position with cash and cash equivalents totaling $273.9 million as of September 30, 2023.

EQS-News: DEFENCE’S SUCCESSFUL SUBMISSION OF AN INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR ACCUTOX® AS AN INJECTABLE ANTICANCER TREATMENT FOR SOLID TUMORS

Retrieved on: 
Saturday, December 30, 2023
Toxicology, Food, Immune system, Biotechnology, IND, Breast cancer, Drug discovery, USOTC, FDA, Immunogenic cell death, City, Melanoma, DNA, Human, Therapy, Cancer, Pharmacokinetics, Investigational New Drug, Animal, Neoplasm, BMS, DNA repair, DTC, Genome, Patient, Pharmacology, Pharmaceutical industry

AccuTOX® is a derivative of the initial Accum® molecule, which has been reported to target cancer on multiple fronts.

Key Points: 
  • AccuTOX® is a derivative of the initial Accum® molecule, which has been reported to target cancer on multiple fronts.
  • In addition, the application describes the manufacture of the drug substance and drug product to be used in human clinical trials.
  • “We are thrilled and excited that Defence has achieved a successful submission on its first IND, which represents an important milestone towards advancing AccuTOX® into the clinic.
  • Several other secondary parameters including therapeutic efficacy will be monitored in treated patients in preparation for a Phase IIa trial on a basket of tumors.

Power Leaves Corp. Provides Update On Transformative Year for Coca Industry

Retrieved on: 
Thursday, December 14, 2023
Petro, Toxicology, Partnership, Government, Classification, Sale, PLC, Chemistry, WHO, Drink, NASA, Perception, Food, World Health Organization, Tier 1, Pharmacology

TORONTO, Ontario, Dec. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Power Leaves Corp. (“PLC”),  a manufacturer of decocainized coca leaf extract reflects on a year of remarkable achievements and significant progress in transforming the global perception and utilization of coca-derived products.

Key Points: 
  • In 2023 PLC achieved critical milestones in commercializing its novel decocainized coca products.
  • PLC signed is first commercial supply agreements for both its Coca Extract and Coca Essence products:
    A $1.35M agreement for the purchase of up to 4,500 litres of PLC’s coca essence product at $100 per litre in 2024, increasing to 9,000L in 2025.
  • A $2.75M agreement for the purchase of 2,500 litres of PLC’s coca extract product at $100 per litre in the first 12-months, increasing to 6,250L per quarter the subsequent 12-months.
  • The WHO's reassessment of the coca leaf can serve as a catalyst to shift global perception of the coca leaf's benefits, aligning with PLC's objectives and products.

ORYZON Awarded with a Grant for ORY-4001 From the ALS Association in the U.S.

Retrieved on: 
Monday, December 4, 2023
ALS, Peripheral neuropathy, Toxicology, HDAC6, Research, Polyneuropathy, Disease, IPSC, CMT, ALS Association, Life expectancy, Respiratory failure, USD, Genomics, Death, Systemic disease, Proteostasis, Neurodegenerative disease, Axonal transport, Diagnosis, Safety, Pharmaceutical industry

The Association has awarded Oryzon a 498,690 USD grant through its Lawrence and Isabel Barnett Drug Development Program to support the regulatory preclinical development of ORY-4001, a highly selective HDAC6 inhibitor, for amyotrophic lateral sclerosis (ALS).

Key Points: 
  • The Association has awarded Oryzon a 498,690 USD grant through its Lawrence and Isabel Barnett Drug Development Program to support the regulatory preclinical development of ORY-4001, a highly selective HDAC6 inhibitor, for amyotrophic lateral sclerosis (ALS).
  • Dr. Jordi Xaus, Oryzon’s CSO, said: “It is an honor to have the support of the ALS Association.
  • Established in 1985, the ALS Association is the largest philanthropic funder of ALS research in the world.
  • The Association is working to make ALS a livable disease while urgently searching for new treatments and a cure.